Jamie Orengo, Ph.D.

Vice President Research, Allergy and Immunity at Regeneron

Speaker

Jamie Orengo, Ph.D., M.P.H., is the Vice President of Allergy and Immunity Research at Regeneron Pharmaceuticals and leads a Research and Discovery group responsible for developing multiple groundbreaking approaches to treat allergic, respiratory and autoimmune disorders that span early to late stages of development. At Regeneron since 2008, Dr. Orengo has delivered preclinical packages for several INDs/BLAs: Dupixent (dupilumab), itepekimab (anti-IL-33), anti-allergen (Fel d 1, Bet v 1), Kevzara (sarilumab), anti-IL-2rg (aplastic anemia), anti-BCMA x anti-CD3 (non-IO). Dr. Orengo has co-authored multiple key scientific journal and media articles featuring Regeneron research. Prior to joining Regeneron, Dr. Orengo completed her doctoral and postdoctoral studies at New York University School of Medicine examining the immune response to malaria parasites. She also received an M.P.H. from Yale School of Public Health studying the epidemiology of microbial diseases and a B.A. in biology from Columbia College, Columbia University.